Treace Medical price target raised to $8 from $7 at Stifel

Stifel raised the firm’s price target on Treace Medical (TMCI) to $8 from $7 and keeps a Hold rating on the shares following what the firm calls “another above-consensus quarterly sales performance.” The full-year guidance “raise-by-the-beat” would seem to reflect management’s aspiration to set achievable performance targets and could leave room for “more-of-the-same” upside potential ahead, the analyst tells investors.